SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ --
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel small-molecule therapeutics, today
reported financial results for the quarter ended March 31, 2008.
Total revenue for the first quarter of 2008 was $2.3 million, with
a net loss of $9.6 million. As of March 31, 2008, cash, cash
equivalents and marketable securities totaled $36.8 million, and
debt totaled $2.1 million. Recent Highlights -- In March, Sunesis
presented positive interim results from the company's ongoing Phase
2 clinical trial of SNS-595 in platinum-resistant ovarian cancer
patients. As of March 10, 2008, these data show that 31 out of 35
women treated with SNS-595, and evaluable for best response using
GOG-RECIST criteria, achieved disease control, including five
investigator-reported objective responses (one of which is
unconfirmed). SNS-595 was generally well tolerated. These data were
presented at the 39th Annual Meeting on Women's Cancer hosted by
the Society of Gynecologic Oncologists. -- Earlier in the year,
based on the safety profile and indications of activity observed at
a dose of 48mg/m2 in Sunesis' Phase 2 clinical trial of SNS-595 in
platinum-resistant ovarian cancer patients, as well as advice
received from clinical investigators, Sunesis amended the protocol
to increase the dose to 60mg/m2 given every 28 days. At the 60mg/m2
dose the company has enrolled more than 30 patients to date.
Reports thus far indicate that SNS-595 is generally well tolerated
at the higher dose with a low incidence of febrile neutropenia.
Therefore, later this month Sunesis plans to submit an amendment to
the protocol to increase the dose intensity by 25 percent to
75mg/m2 given every 28 days. Sunesis expects to enroll
approximately 30 patients at this new dose level by the end of this
year. -- In April, Sunesis presented data on all three of its
clinical-stage product candidates, SNS-595, SNS-032 and SNS-314, at
the American Association for Cancer Research (AACR) Annual Meeting
in San Diego, California. - Results from multiple nonclinical,
translational research studies of SNS-595 presented by Sunesis
researchers provide further insights into the compound's mechanism
of action and activity in certain types of cancers. SNS-595 acts by
site-selective DNA intercalation and topoisomerase II poisoning
resulting in apoptosis, or cell death. SNS-595's targeted
DNA-topoisomerase II interactions and selectivity for proliferating
cells may contribute to the broad therapeutic window observed to
date in patients treated with SNS-595. SNS-595 is not a
P-glycoprotein substrate and its activity is independent of the p53
family, suggesting that SNS-595 may be able to overcome these
common drug resistance mechanisms. A Phase 2 single agent clinical
trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of
SNS-595 in combination with cytarabine in relapsed/refractory AML
are ongoing. - SNS-032, a potent and selective inhibitor of
cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase
1 clinical trial in patients with relapsed/refractory chronic
lymphocytic leukemia or multiple myeloma. An oral presentation by
Suzanne Trudel, MSc, M.D., Assistant Professor, Princess Margaret
Hospital, University Health Network in Toronto, Canada, focused on
the results from studies of SNS-032 demonstrating broad,
mechanism-based activity in human myeloma cell lines and primary
multiple myeloma cell cultures both as a single agent and in
combination with either bortezomib (Velcade(R)) or lenalidomide
(Revlimid(R)). A poster presentation by William Plunkett, Ph.D.,
Professor and Chief, Section of Molecular and Cellular Oncology at
The University of Texas MD Anderson Cancer Center showed that
SNS-032 blocks the transcription of key oncoproteins associated
with mantle cell lymphoma. - SNS-314 is a potent and selective
pan-Aurora kinase inhibitor being studied in a Phase 1
dose-escalating clinical trial in patients with advanced solid
tumors. Nonclinical research presented at the AACR Annual Meeting
demonstrate that SNS-314 inhibits tumor growth in human xenograft
models of colorectal, prostate, non-small cell lung and AML.
Biomarker analyses of these nonclinical studies confirm SNS-314's
targeted, sustained activity and favorable pharmacokinetics. -- In
March and April, Sunesis filed three patent applications related to
its next generation fragment-based drug discovery. This technology
combines the advantages of fragment assembly with high-throughput
screening to generate diverse, novel starting points for medicinal
chemistry. This proprietary technology platform can be applied to
large proteins or protein complexes, significantly expanding the
types of targets that the company can address, while reducing the
time and manpower required for lead identification. To date, this
approach has been applied successfully to several new drug targets,
including anaplastic lymphoma kinase (ALK). Pilot screens against
other targets, including protein:protein systems, are underway. --
Sunesis received a preclinical milestone payment in February from
Johnson & Johnson Pharmaceutical Research & Development,
L.L.C. (J&JPRD) under the companies' drug discovery
collaboration. The milestone payment was triggered by J&JPRD's
selection of a compound targeting the Cathepsin S enzyme as a
development candidate emerging from the research collaboration.
Financial Highlights -- Collaboration revenue totaled $2.3 million
for both the three months ended March 31, 2008 and the three months
ended March 31, 2007. -- Research and development (R&D) expense
was $8.7 million for the first quarter of 2008 compared to $9.3
million for the same period in 2007. The quarter-over-quarter
decrease in R&D expense resulted primarily from a decrease in
expense related to the SNS-314 and kinase inhibitor programs,
partially offset by higher expense for the development of SNS-032
and SNS-595 due to increased clinical trial activities. -- General
and administrative (G&A) expense for the first quarter of 2008
was comparable to the same period last year. G&A expense was
$3.3 million for both the 2008 and 2007 periods. -- In the first
quarter ended March 31, 2008, Sunesis recorded an additional $0.3
million real estate-related, non-cash, restructuring charge in
conjunction with the company's reorganization and reduction in
force in 2007. -- Sunesis reported a net loss of $9.6 million for
the quarter ended March 31, 2008 compared to a reported net loss of
$9.4 million for the three- month period ended March 31, 2007. --
In the first quarter of 2008, Sunesis recorded non-cash stock
compensation expense of $0.7 million. Conference Call Information
Sunesis' management will host a conference call to review the
results of the first quarter today at 11:00 a.m. EDT. Individual
and institutional investors can access the call via (877) 440-5786
(U.S. and Canada) or (719) 325-4929 (international). To access the
live audio webcast or the subsequent archived recording, visit the
"Investors and Media - Calendar of Events" section of the Sunesis
website at http://www.sunesis.com/. Please log on to Sunesis'
website several minutes prior to the start of the presentation to
ensure adequate time for any software download that may be
necessary. The webcast will be recorded and available for replay on
the company's website until May 22, 2008. About Sunesis
Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel small-molecule therapeutics for oncology and other serious
diseases. Sunesis has built a broad product candidate portfolio
through internal discovery and in-licensing of novel cancer
therapeutics. Sunesis is advancing its product candidates through
in-house research and development efforts and strategic
collaborations with leading pharmaceutical and biopharmaceutical
companies. For further information on Sunesis Pharmaceuticals,
please visit http://www.sunesis.com/. SUNESIS and the logo are
trademarks of Sunesis Pharmaceuticals, Inc. All other trademarks,
trade names and service marks appearing in this press release are
the property of their respective owners. Safe Harbor Statement This
press release contains forward-looking statements including without
limitation statements related to the potential safety and efficacy
and commercial potential of SNS-595, SNS-032 and SNS-314, planned
additional clinical testing and development efforts, the timing of
protocol amendments, the announcement of clinical results and the
significance of new patent applications, the company's ability to
obtain patents on the underlying technology and the key benefits of
the underlying technology. Words such as "support," "will,"
"plans," "indicate," "possible," "optimistic," "may," "suggests,"
"expects," "designed" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Sunesis' current expectations.
Forward-looking statements involve risks and uncertainties.
Sunesis' actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the risk that Sunesis' drug discovery
and development activities could be halted significantly or delayed
for various reasons, the risk that Sunesis' clinical trials for
SNS-595, SNS-032 and SNS-314 may not demonstrate safety or efficacy
or lead to regulatory approval, the risk that preliminary data and
trends may not be predictive of future data or results, the risk
that Sunesis' preclinical studies and clinical trials may not
satisfy the requirements of the FDA or other regulatory agencies,
risks related to the conduct of Sunesis' clinical trials and
manufacturing of SNS-595, SNS-032 and SNS-314, risks related to
Sunesis' need for additional funding and the risk that Sunesis'
proprietary rights may not adequately protect the company's
technologies and product candidates. These and other risk factors
are discussed under "Risk Factors" and elsewhere in Sunesis' annual
report on Form 10-K for the year ended December 31, 2007 and other
filings with the Securities and Exchange Commission. Sunesis
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
Sunesis Pharmaceuticals, Inc. Consolidated Statements of Operations
Three months ended March 31, 2008 2007 (unaudited) Revenue:
Collaboration revenue $537,500 $229,167 Collaboration revenue from
related party 1,765,683 2,037,099 License revenue - 250,000 Total
revenues 2,303,183 2,516,266 Operating expenses: Research and
development 8,742,895 9,307,478 General and administrative
3,266,129 3,296,147 Restructuring charges 320,774 - Total operating
expenses 12,329,798 12,603,625 Loss from operations (10,026,615)
(10,087,359) Interest income 460,412 769,626 Interest expense
(59,373) (52,043) Other income, net 671 739 Net loss $(9,624,905)
$(9,369,037) Basic and diluted loss per share $(0.28) $(0.32)
Shares used in computing basic and diluted loss per share
34,364,896 29,457,247 Sunesis Pharmaceuticals, Inc. Consolidated
Balance Sheets March 31 December 31 2008 2007 ASSETS (unaudited)
(Note 1) Current assets: Cash and cash equivalents $6,235,762
$11,726,126 Marketable securities 30,581,908 35,957,933 Prepaids
and other current assets 1,463,390 945,583 Total current assets
38,281,060 48,629,642 Property and equipment, net 3,971,051
4,238,498 Deposits and other assets 377,798 377,798 Total assets
$42,629,909 $53,245,938 LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities: Accounts payable and other accrued liabilities
$4,475,117 $4,515,426 Accrued compensation 1,405,065 2,225,868
Current portion of deferred revenue 752,032 1,227,031 Current
portion of equipment financing 885,286 953,940 Total current
liabilities 7,517,500 8,922,265 Non current portion of equipment
financing 1,164,819 1,352,684 Deferred rent liabilities 1,472,418
1,576,734 Total liabilities 10,154,737 11,851,683 Commitments
Stockholders' equity: Common stock 3,437 3,437 Additional paid-in
capital 321,116,162 320,579,240 Deferred stock-based compensation
(134,619) (251,601) Accumulated other comprehensive income 121,180
69,262 Accumulated deficit (288,630,988) (279,006,083) Total
stockholders' equity 32,475,172 41,394,255 Total liabilities and
stockholders' equity $42,629,909 $53,245,938 Note 1: The
consolidated balance sheet at December 31, 2007 has been derived
from the audited financial statements at that date included in the
Company's Form 10-K for the fiscal year ended December 31, 2007.
DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT: Investors: Eric
Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc., +1-650-266-3717;
or Media: Karen L. Bergman, +1-650-575-1509, or Michelle Corral,
+1-415-794-8662, both of BCC Partners Web site:
http://www.sunesis.com/
Copyright
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024